Potential opportunities and challenges for infection prevention and control for cystic fibrosis in the modern era.
Curr Opin Infect Dis
; 35(4): 346-352, 2022 08 01.
Article
in English
| MEDLINE | ID: covidwho-2032207
ABSTRACT
PURPOSE OF REVIEW We describe recent changes in care for people with cystic fibrosis (PwCF) that could impact infection prevention and control (IP&C) practices. RECENT FINDINGS:
Current IP&C guidelines primarily aim to prevent acquisition and transmission of pathogens in PwCF utilizing evidence-based recommendations for healthcare settings. Currently, highly effective modulator therapy (HEMT) is dramatically improving the clinical manifestations of cystic fibrosis and reducing pulmonary exacerbations and hospitalizations. Thus, it is feasible that long-term, sustained improvements in pulmonary manifestations of cystic fibrosis could favorably alter cystic fibrosis microbiology. The COVID-19 pandemic increased the use of virtual care, enabling PwCF to spend less time in healthcare settings and potentially reduce the risk of acquiring cystic fibrosis pathogens. The increasing use of whole genome sequencing (WGS) shows great promise in elucidating sources of cystic fibrosis pathogens, shared strains, and epidemic strains and ultimately could allow the cystic fibrosis community to monitor the safety of changed IP&C practices, if deemed appropriate. Finally, given the nonhealthcare environmental reservoirs for cystic fibrosis pathogens, practical guidance can inform PwCF and their families about potential risks and mitigation strategies.SUMMARY:
New developments in the treatment of PwCF, a shift toward virtual care delivery of care, and use of WGS could change future IP&C practices.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Cystic Fibrosis
/
COVID-19
Type of study:
Prognostic study
Limits:
Humans
Language:
English
Journal:
Curr Opin Infect Dis
Journal subject:
Communicable Diseases
Year:
2022
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS